allows an elaborated genetic analysis of brain tumours and opens the door to individualised therapies. Psychiatric disorders remain the area where progress is slow. Genetic analyses show that for major common disorders such as schizophrenia and depression there are no single gene alterations which offer options for targeted therapy development. However, new approaches are being developed to leverage genetic information to predict patients' responses to treatment. These recent developments hold promise for early diagnosis, follow-up with personalised treatments with adjusted therapeutic doses, predictable responses, reduced adverse drug reactions, and personal health planning. The scenario is promising but calls for increased support for curiosity-driven research into the mechanisms of normal brain functioning as well as challenging adaptations of health care and research infrastructures, encompassing legal frameworks for analysing large amounts of personal data, a flexible regulatory framework for correlating big data analyses in cooperative networks between academia and the drug development industry, and finally new strategies for brain banking in order to increase access to brain tissue samples.
Introduction
Brain disorders comprise a variety of complex diseases of the nervous system, including psychiatric, neurological, and neurosurgical conditions. As a whole, brain disorders represent one of the greatest threats to public health [1] [2] [3] . Across Europe, millions of people of all ages struggle with brain disorders. These are often long-term conditions which severely affect the quality of life and are frequently associated with considerable disability and sometimes a reduced life expectancy. As a result, they have an enormous impact on patients and their families and, more broadly, on the European economy. In Europe, the total annual cost of brain disorders was estimated at EUR 798 billion in 2010, with an average cost per inhabitant of EUR 5,550 [4] . As the population is ageing, the incidence of brain disorders will increase even more, and therefore the broad impact of brain disorders in the future is likely to be greater, with important implications for European economic growth.
Because of their wide spectrum and complex and often ill-understood aetiology, brain disorders pose major challenges to medicine and treatment innovation. It is now clear that brain disorders have a strong genetic component, which confers susceptibility or resistance and influences the severity and progression of the disease. The complexity of this genetic component can vary greatly across brain disorders. While some are monogenic, meaning that they result from mutations in one single gene, the prevalence of polygenic disorders, resulting from the interplay of multiple genes and environmental factors, is much higher. However, the distinction between these two extremes can be imprecise, since even in the case of monogenic brain disorders, cooperating genetic or epigenetic factors can alter several aspects of the disease such as its onset, evolution, and response to treatment [5] . In recent years, the advent of new genomic technologies and advances in our understanding of normal brain function have offered the possibility of dissecting the genetic or epigenetic components of brain disorders and opening the door to personalised medicine.
The effective application of genomic findings to clinical practice holds the promise to determine predispositions to diseases, to deliver timely targeted preventions, and to tailor the right therapeutic strategy to the right patient at the right time. Several health care strategies integrate genomic data into clinical research and practise as markers for diagnosis, prognosis, and prevention as well as targets for treatment [6] . In particular, the identification of genetic markers associated with a disease allows for an accurate diagnosis, prognosis, and correlation to follow-up of the disease. Furthermore, it serves as the basis for the design of preventive strategies that minimise the risk of developing the disease and of therapeutic approaches according to a person's genetic makeup. Finally, analysis of genomic information by uncovering the biological mechanisms of normal brain function and how these cause the disease can influence our approach to developing new drugs. Thus, a genome-based personalised medicine approach should play an important role in promoting health and combating brain disorders by completely shifting the therapeutic paradigm from 'one-fitsall' and 'trial-and-error' prescription to a personalised concept of treatment tailored to the specific genetic signature of a patient, i.e. gene-tailored treatment. Potentially, this should lead to better-powered clinical trials able to detect expected subgroup efficacies for new drugs, rather than discarding such drugs as being ineffective for the general population.
While recent advances and issues related to personalised medicine for brain disorders have been more extensively reviewed elsewhere [7] [8] [9] [10] [11] [12] , in this article we have chosen only few examples as paradigms of neurological, neurosurgical, and psychiatric conditions which emphasise the major scientific challenges facing the discipline. In addition, we also discussed 'brain-specific' practical and ethical challenges related to genetic/epigenetic disease assessment, brain banking, and patient involvement.
Neurological Disorders: Huntington's Disease
Huntington's disease (HD) is characterised by a complex phenotype including motor, cognitive, and psychiatric symptoms and signs starting at different ages and steadily worsening until death after around 15-25 years [13, 14] . The cause is a dynamic mutation with expansion of a CAG repeat in the huntingtin (HTT) gene [15] , which is transcribed into an abnormal protein with an elongated polyglutamine tract. Polyglutamine HTT accumulates in the affected brain [16] , and protein function is changed in multifaceted ways related to the numerous roles of the normal protein [17] . One way to handle the disturbed protein is to silence HTT gene transcription, which leads to a decrease in abnormal protein content.
Several strategies aimed at decreasing expression of the abnormal elongated allele of the HTT gene are in the process of development in animal models in the hope that lower levels of the abnormal protein would rescue disturbed molecular pathways and decrease neuronal cell death. They include antisense oligonucleotides (ASOs), interfering RNA molecules, and proteins modulating the transcription process. A decrease in HTT expression improves symptoms and prolongs survival in HD mouse models [18, 19] . Specifically, HTT mRNA-targeted ASOs [20] induce its degradation by RNases and can be modified to be resistant to exonuclease cleavage, thereby improving their stability. After injection into the brain of HD animal models, HTT mRNA levels in the striatum are lowered without any morphological damage [21] . A safety trial with intrathecally injected ASOs is underway (ClinicalTrials.gov identifier: NCT02519036). Small interfering RNA or microRNA binds to the abnormal HTT transcript, leading to its degradation by the RNA-induced silencing complex with a consecutive decrease in mutated protein; this approach has been found to improve the phenotype in animal models [22] . The molecule may be packaged into modified adenoviruses acting as a vector, and stereotactic injections of such constructs have been found to be safe in primates for 6 months [23] . This treatment is followed by a significant decrease in HTT mRNA as compared with controls.
Such precision treatment performed in a specific way according to gene mutation may be personalised further in order to target only the mutant gene transcript, leaving the normal one untouched. This would allow expression of the normal protein with conservation of its multifaceted functions and a suggested protective function in the HD brain affected. Instead of general silencing, such a strategy would use DNA or RNA specifically recognising the elongated allele only in a selective (allele-specific) way, leading to degradation of the abnormal, elongated mRNA with a consecutive decrease in abnormal protein content. Such selectivity may be achieved by targeting single nucleotide polymorphisms found only on the abnormal allele, on top of targeting the expanded CAG repeat part. Small interfering RNA may be designed to specifically target the mutant allele in a selective way, with conservation of normal wild-type HTT expression [24] . Patients with elongated CAG repeats, a status which will eventually lead to full penetrance of the disorder, may be selected for target therapy according to the presence of specific single nucleotides on the allele with elongated CAG repeats [25] . Only patients who are homozygous at the targeted single nucleotide sequence would not be candidates for such personalised therapy.
Since the single cause of HD is known precisely, and can be confirmed long before disease onset, this disorder may be considered a paradigm of disease-modifying treatment of other monogenic neurodegenerative disorders. Furthermore, there is a long presymptomatic phase during which methods for disease-modifying treatment might be tested and applied.
Neurosurgical Disorders: Brain Tumours
Primary or intrinsic brain tumours (gliomas) arise from glia, are confined to the brain, and carry an extremely poor prognosis which is determined by their diffusely infiltrative nature involving the whole brain, precluding curative resection and precluding access to most antitumour drugs. The specific neurobiology of these tumours and brain physiology as such add significantly to the underlying oncological challenge. Nevertheless, apart from the underlying issue of drug delivery to the brain, a more elaborate genetic analysis of brain tumours has increasingly allowed thinking along the concepts of individualising therapies for brain tumour patients as well [26, 27] .
The search for gene mutations specific to gliomas already began with the emergence of cancer genomics. At first, oncogenes and then tumour suppressor genes were found [28, 29] . More than 20 years ago, it turned out that chromosomal 1p/19q deletions described oligodendroglial tumours very well and allowed for therapeutic decisions which have since been proven valid in clinical trials after more than a decade of follow-up [30] . Many more specific gene mutations have been found thereafter, with epidermal growth factor receptor mutations [31] and isocitrate dehydrogenase (IDH)1/IDH2 mutations [32] being the most recent. In addition, epigenetic modifications such as in the MGMT gene have been shown to be relevant to the response to chemotherapeutics [33] .
Very few of these molecular genetic discoveries have led to therapeutic opportunities, mostly because of a lack of substances effectively able to penetrate into the brain. Nevertheless, some current therapeutic developments are based on such genetic insights, such as the development of a peptide vaccination against a unique epitope of the mutated epidermal growth factor receptor, which led to a phase III trial on glioblastoma with results awaited in 2016; likewise, there is an early clinical trial effort regard-ing vaccination against a mutant IDH1 peptide sequence. Determination of MGMT gene methylation has led to stratification of clinical trials and even categorical adaptation of temozolomide chemotherapy in elderly glioblastoma patients, a first step towards personalised medicine [34] .
Meanwhile, several considerable efforts by consortia have arrived at a characterisation of gene expression subtypes of glioblastoma and the dynamics of shifting patterns as well as their relation to therapy and prognosis, but they have not yet translated into clinical practice. This extends also into the area of less aggressive, earlier, 'lowgrade' lesions, which may offer an even more beneficial opportunity for therapeutic intervention, since the disease has not progressed as far [35] . It is becoming evident that there is more knowledge available than adequately analysed for its clinical implications [36] and that large databases and appropriate bioinformatics are needed to correlate outcomes and treatment efficacies with gene profiles. Most advanced in this respect -also regarding the availability of targeted drugs -is paediatric neurooncology in the field of medulloblastoma research [37] [38] [39] . With effective targeted agents for distinct genetic subgroups, survival and prognosis have been diversified/ personalised dramatically.
Only of late, with improving methods of detecting gene mutations as such or specific molecules derived thereof in the circulation, biomarkers have been defined [40, 41] which need to be taken into consideration for clinical trial design up front to account for efficacies among subgroups. When condensing all genetic knowledge about intrinsic brain tumours, there are a sufficient number of genetic alterations known to allow for genetailored personalised treatment.
Psychiatric Disorders
Psychiatric disorders remain the one area where progress is slower. One of the obvious applications of an increased genetic understanding of the main psychiatric disorders is in leveraging this knowledge to better understand patients' likely responses to treatment. However, due to the complexity of this group of diseases, success has been limited when using conventional methodologies, with which only small pathways around specific target genes are investigated. It is likely that even though there is a genetic contribution to psychiatric conditions, no one obvious, simple link will be reported between an individual gene and its polymorphisms or changes in gene expression and treatment response. This should not be surprising in light of the complex genetic architecture of these conditions as well as the multitude of changes at the gene expression and protein levels. Consequently, complementary routes addressing the question of individualising a patient's treatment need to be considered in addition to the conventional approach. An alternative approach is to base the search on the whole genome, thereby taking advantage of the ability to make multiple tests during the search for associations. The benefit of such an approach is to allow for the additive effect of finding what may individually be weak signals. This seems a reasonable approach in light of what is now known about the genomic structure of, for example, schizophrenia, which is highly heritable but a polygenic burden primarily arising from rare, disruptive mutations distributed across many genes [42] .
One clear lesson from the investigation of genetic risk association studies has been the need to generate sufficient sample sizes in order to be in a position to identify significant associations. To explore the question of treatment response is also likely to require relatively large sample sizes. This has proven possible in the search for genetic variants associated with response to lithium treatment in bipolar disorder [43] . Lithium responses from 2,563 patients were collected and tested for genomic associations, and one locus was identified which conferred a significantly lower rate of relapse in an independent test. If this result could be confirmed, this locus would represent a novel genetic biomarker for lithium response, but its relatively low frequency within the population diminishes its direct clinical importance. It may still prove clinically relevant if more such loci could be identified and combined in an informative manner.
Another source of potential variability in the response to antipsychotic treatment has been reported to be associated with epigenetic changes in mGLU2 promoter activity as a potential consequence of long-term treatment. Similarly, an investigation into the potential utility of DNA methylation changes in IL-11 in predicting the response to antidepressants in patients with major depressive disorder showed the viability of this approach [44] .
In view of the current progress that has been made and the clear scope for further improvement in the area of predicting treatment response, a number of suggestions can be made. One is to increase the power to detect signals through an increase in sample size. While it is a challenge to enrol large cohorts, there is a clear prospect for success based on the results achieved in the search for risk association signals [45] . For example, a common polygenic variation was shown to account for at least one third of the total variation in schizophrenia risk when 1 million SNPs were tested in more than 8,000 patients and 19,000 controls [42] . Another avenue to follow is to combine genomic data sets, that is, to combine genetic variation in other types of -omics data sets (e.g. variation in DNA methylation status or proteomic data). This makes sense biologically, since there are many kinds of input into treatment response beyond genetic ones. Bioinformatic techniques have been developed to allow searching these large data sets in an informed manner, and they can uncover biologically meaningful relationships.
Another key aspect is limited access to the brain and the need for approaches that permit acquiring information from the periphery. In this respect, a new opportunity to overcome the problem of tissue availability is provided by the use of epigenetic markers, which, while reflecting what is occurring in the brain, are accessible through peripheral tissues via blood, urine, and saliva. Underlining the validity of such an approach, an analysis of epigenetic markers from the blood of patients with major depressive disorder has recently led to the identification of a potential target for novel antidepressant treatments [31] . Likewise, there has been some success in identifying blood-based biomarkers which may predict schizophrenia prior to disease onset [46] or dysregulation of the brain in patients with autism spectrum disorder [47] .
Another area that needs to be considered is integration of comorbidities such as suicide and suicidal behaviours. Genetic and epigenetic biomarkers are beginning to be uncovered, such as SKA2, which has been linked to suicidal behaviour, anxiety, and stress [48, 49] . As well as being studied further for its own sake, an important question that remains is if there is any interaction with comorbid conditions.
Overall, while important progress has been made in beginning to develop individualised treatments for psychiatric disorders, major challenges remain along the way of bringing treatments from the bench to clinical practice.
'Brain-Specific' Challenges to Personalised Medicine
The ultimate goal in personalised medicine for brain disorders is to improve current patient care and accelerate future drug therapies. We have discussed some of the recent developments in this discipline that hold promise for personalised treatments with an early diagnosis, adjusted therapeutic doses, predictable responses, reduced adverse drug reactions, and personal health planning. The scenario is exciting, but at the same time, this new approach faces crucial scientific, policy, and ethical issues that need to be addressed in order to translate the scientific discoveries responsibly into clinical applications for the benefit of patients.
While many of those issues do not differ significantly between brain disorders and other therapeutic areas such as cancer, the limited access to the brain and the scarcity of brain tissue are surely of the utmost concern. Strictly speaking, brain tumours are part of the cancer field, and, accordingly, the tiny advances made towards personalised medicine rely on the availability of tissue; this has been easiest with leukaemias, which are consequently the most successfully treated oncological conditions. For many brain diseases, mostly degenerative or psychiatric, acquisition of brain specimens is possible solely via brain banking once patients have succumbed to their disease.
Thus, access to human brain tissue is crucial to further advance our knowledge of associations between particular genes and brain disorders, which is paramount for the development of personalised therapies. Brain banks have been indispensable to our understanding of the pathology of many brain disorders, including Alzheimer's and Parkinson's [50] , and they remain powerful resources for brain research. However, brain banking faces a set of challenges that hamper progress in this area. Brain banks are faced with a decline in clinical autopsy rates and with the scarcity of brain donors. This is because the current legal regulations pose obstacles to brain autopsies and many clinicians have lost clinical interest in brain autopsy or are reluctant to talk about postmortem organ donation with their patients and the patients' relatives. To overcome this problem, donor programmes may be particularly effective in raising awareness among the public and in establishing a dialogue with patients that would lead to an increase in autopsies and brain donations. Decreases in autopsy rates and brain donations necessitate collaboration across national and state borders by the establishment of brain networks such as BrainNet Europe (http://www.brainnet-europe.org). This allows access to larger numbers of shared control cases and brains from patients with brain disorders. However, efficient networking requires the standardisation of protocols, diagnostic procedures, and data acquisition so that samples and data are comparable. Although several recommendations regarding how to operate brain banks have been issued, globally accepted standard protocols or regulations for the banking of brain tissues are still missing.
From an ethical point of view, premortem written informed consent to brain donation is indisputably the way to respect the autonomous decision of potential donors. However, if patients or other persons die without having prepared a written informed consent, it is conventional in most countries to request from relatives (next of kin) a statement regarding the presumptive wish of the deceased for a clinical autopsy or brain donation. Because ethical and legal conditions vary between countries, and because many countries that lack legal regulations act by customary rights, a code of conduct that satisfies the requirements of all members must be established for brain bank networks collecting brains from multiple countries or states. Moreover, particular ethical considerations are required to be made for banking the brains of patients with psychiatric disorders, especially concerning consent issues. In these cases, potential donors should be encouraged to take their time taking their decision in order to ensure that individuals with fluctuating decision-making capacity do not act on impulse.
Finally, brain banks have the possibility of obtaining more support from the public if they successfully convey the advantages of their work. This may be achieved by publicising the notion that brain banking is indispensable for progress in medicine, as well as by making brain banking procedures more transparent to the public. This awareness campaign will have to address problems of autopsy acceptability, misconceptions regarding research that can be performed on human postmortem tissues, the need to obtain support for brain banks from government sources or the private sector, as well as the need to increase the number of brain tissue donors.
A large number of challenges must be addressed before personalised medicine for brain disorders can become a reality. Each of these challenges must be dealt with not by a single person or group but by all of the stakeholders that are affected by it. In this respect, patients and patient organisations represent important stakeholders in the whole process of personalised medicine. Nevertheless, to ensure an effective and responsible involvement of patients, crucial information has to be provided, most importantly a clear, comprehensible explanation of the term 'personalised medicine', together with knowledge about the possibilities, limitations, risks, and consequences of this innovative approach.
Related to the issue of brain banking, patient organisations and specific disease focus groups must realise that once correlations can be made between genomic information that allows for disease subclassification (as in 'dementia'), biomarkers might be developed which may reflect the disease in any biospecimen taken alive. If an epigenetic change or a mutation occurred only in a diseased subject's brain, an awareness must be built that an adequate personalised therapeutic decision can only be made based on tissue, requiring a biopsy. With exosomal analysis technology there is hope that in the future many diseases may be defined from 'liquid biopsies', but until this becomes available, much correlative work has to be performed between patients, academic consortial genomics or other omics and the pharma industry to personalise medicine as much as possible.
National information points have to be implemented to assist patients in taking decisions on their health plans or lodging complaints. This will both protect patients and preserve patient rights whilst also benefitting the progress made in the area. These information points should be organised at the national level and monitored at the European level, making it possible for anyone to acquire the correct information in their own language but with trust, transparency, and quality control implemented at all times. Relevant stakeholders should have access to appropriate information in order to evaluate and enhance their techniques, care pathways, diagnostics, treatments, etc., which can then benefit all member states, giving everyone access to personalised diagnosis and treatment of the same quality.
Patient organisations, at the European and national levels, are a big asset via their extensive patient expertise. Their close partnership with patients puts them in a unique position within the whole process. Patient organisations build on trust, making it possible to gather large amounts of disease-specific data, to inform patients about their disease, treatment, and everyday life, and to give patients a voice by representing them and providing patient-centred information to all stakeholders. When involving patient organisations at the European and national (regional) levels, funding and recognition should be considered to support them in this role. Properly informed patients and patient organisations have been proven to be beneficial to researchers and other stakeholders, and involving them at the beginning of the process saves precious time and money.
Finally, advances in our understanding of the specific biological mechanisms that lead to brain disease will be directed by insights generated from basic research into the biology that supports normal brain function. Technological advances are helping neuroscientists of our time approach questions related to the regulation of complex behaviour at all levels and in all species including humans. An improved understanding of how specific be-havioural traits are fundamentally associated with the neuronal circuitry of the brain and its underlying regulation of molecular and neurotransmitter systems will support an improved comprehension of disease mechanisms and thus better support for developing new strategies for the prevention and treatment of brain disorders.
Conclusions
The rapid development of genome-based technologies holds the promise of an effective application of genetic information to the development of individualised therapies for patients with brain conditions. Strategies for the use of individualised treatment and prevention of brain diseases will furthermore emerge from the rapidly advancing field of molecular and behavioural neuroscience.
We are just at the beginning of a paradigm shift, and a large number of scientific, policy, and ethical challenges must be addressed before gene-tailored treatments for brain disorders become a reality. The changing paradigm requires demanding adaptations of health care and research infrastructures, encompassing legal frameworks for analysing large amounts of personal data, a flexible regulatory framework for correlating big data analyses in cooperative frameworks between academia and the drug development industry, and finally new strategies for brain banking in order to increase access to brain tissue samples.
A joint effort of all relevant stakeholders is required to overcome these challenges and make gene-tailored treatment for brain disorders a reality. In this respect, patients and patient organisations represent important stakeholders and should be involved in the process at an early stage and provided with resources to do so. By raising awareness of brain disorders and personalised medicine, healthy subjects may be stimulated to participate and brain disorders may be focused on in a wider sense. An open dialogue with all stakeholders coordinated at the EU level needs to take place as we try to put a framework for personalised medicine in place which allows room for ethical questions to be addressed.
